Identity
a meroterpene phenol — a plant-derived molecule combining a monoterpene tail with a phenolic head — first isolated in 1966 from the seeds of Psoralea corylifolia, a leguminous plant native to India and China (common names: babchi, bakuchi). Molecular formula C₂₂H₃₄O₂. Notably, bakuchiol has no structural resemblance to vitamin A or the retinoids — it is not a vitamin, not a retinoid, and does not bind retinoic acid receptors. Its similarity to retinol is entirely functional, not structural.
Purity matters: to carry the INCI name "Bakuchiol" an ingredient must be >80% pure. Unpurified Psoralea corylifolia extracts and babchi seed oils contain other phytochemicals — including psoralen and isopsoralen (furocoumarins) — that are photosensitising and can cause serious skin reactions on sun exposure. These fall under different INCI names (e.g., "Psoralea corylifolia seed extract"), have different safety profiles, and should not be confused with purified bakuchiol.
Development & history
- 1966: Bakuchiol first isolated and structurally characterised from Psoralea corylifolia seeds.
- Ancient use: the parent plant has centuries of use in Ayurvedic and Traditional Chinese Medicine for a broad range of skin conditions — traditional context, not modern efficacy data.
- 2007: First commercial cosmetic introduction as Sytenol A by Sytheon Ltd (New Jersey, US) — the ingredient supplier that would go on to publish the foundational mechanistic paper.
- 2014: Chaudhuri & Bojanowski publish comparative gene expression profiling in International Journal of Cosmetic Science, positioning bakuchiol as a "functional analogue" of retinol. This paper is widely cited and mechanistically important — but its authors are Sytheon employees with commercial interest in the ingredient.
- 2019: Dhaliwal et al. publish the pivotal independent clinical trial in British Journal of Dermatology: 12-week randomised, double-blind, split-comparison of bakuchiol 0.5% vs retinol 0.5% (n=44). Parity for wrinkle and hyperpigmentation reduction; better tolerability for bakuchiol. This trial launched bakuchiol into mainstream skincare consciousness.
- 2020–2024: Multiple additional clinical evaluations and mechanistic studies published (Draelos 2020 in sensitive skin, Goldberg 2020 with combined actives, Bluemke 2022 independent multidirectional efficacy). Ingredient adoption across cosmetic brands accelerates.
- 2024–2026: Bakuchiol is now one of the fastest-growing search categories in cosmetic ingredients (approximately +49% year-over-year in trend data), driven partly by consumer interest in retinol alternatives — accelerated by the November 2025 EU restrictions on retinol under Regulation (EU) 2024/996.
Mechanism (as proposed)
despite lacking structural similarity to retinoids, bakuchiol induces a gene expression signature in skin cells that broadly overlaps with retinol's — upregulating type I, III, and IV collagen, aquaporin 3 (hydration), and modulating matrix metalloproteinases (MMP-1 inhibition and, notably, stronger MMP-12 inhibition than retinol itself). It does this without binding retinoic acid receptors (RAR/RXR); instead, it acts through MAPK/ERK signalling, PI3K/Akt, and — per more recent proteomic work — direct interactions with FABP5 and multiple kinases. Bakuchiol is also a potent lipid-peroxidation inhibitor — approximately 60× more effective than natural tocopherol at protecting squalene from photo-oxidation in vitro. Because the pathway is different, bakuchiol delivers retinol-like benefits without the retinization period (initial irritation, dryness, peeling) that comes with true retinoid receptor activation, and without the cumulative vitamin A exposure concerns that led to the 2024–2025 EU retinol restrictions.